Charles River Labs Q3 2026: EPS up 27% while revenue guidance rises
As seen on the 24/7 Wall St. homepage on November 4, 2026.
Charles River pulled 27.2% adjusted EPS growth out of a revenue base that still shrank, and raised its full-year revenue outlook above the Street. A firming read on pharma R&D demand.
CHARLES RIVER $CRL Q3’26 EARNINGS HIGHLIGHTS 🔹 Revenue: $982.7M (Est. $959M) 🟢; -2.2% YoY 🔹 Adj. EPS: $3.09 (Est. $2.97) 🟢; +27.2% YoY 🔹 Non-GAAP Oper Income: $225.8M (Est. $217M) 🟢 Raises FY26 Guide: 🔹 Reported Revenue Growth: -2.0% to -1.5% (Est. -2.5%) 🟢 🔹 Adj. EPS: https://t.co/TnbC3KRl6Y
- Replies4
- Reposts3
- Likes17
Continue ReadingShow less
Charles River Laboratories posted third-quarter revenue of $982.7 million against a consensus estimate of $959 million, beating expectations even as the top line contracted 2.2% from a year ago. The company is wringing more efficiency out of its operations than the Street had priced in.
Adjusted EPS of $3.09 came in above the $2.97 estimate and represented 27.2% growth year over year, a striking margin expansion story given that revenue was still moving in the wrong direction. Non-GAAP operating income also topped estimates, reinforcing that the profitability improvement runs through the income statement.
Sponsored
Management lifted its full-year reported revenue growth outlook to a range of negative 2.0% to negative 1.5%, better than the Street's estimate of negative 2.5%. The revenue contraction is shallower than feared and is stabilizing.
For anyone tracking pharma and biotech R&D spending as a demand signal, a beat-and-raise from a contract research organization of this scale is a meaningful data point. It suggests clients are sustaining or modestly accelerating their outsourced research budgets rather than pulling back further.
Mentioned: CRL